Back to Browse Journals » OncoTargets and Therapy » Volume 2

Targeting cancers in the gastrointestinal tract: role of capecitabine

Authors Muhammad Wasif Saif

Published 25 March 2009 Volume 2009:2 Pages 29—41


Review by Single-blind

Peer reviewer comments 2

Muhammad Wasif Saif

Yale Cancer Center, Yale University School of Medicine, New Haven, CT, USA

Abstract: Capecitabine is currently the only novel, orally home-administered fluorouracil prodrug. It offers patients more freedom from hospital visits and less inconvenience and complications associated with infusion devices. The drug has been extensively studied in large clinical trials in many solid tumors, including breast cancer, colorectal cancer, gastric cancer, and many others. Furthermore, the drug compares favorably with fluorouracil in patients with such cancers, with a safe toxicity profile, consisting mainly of gastrointestinal and dermatologic adverse effects. Whereas gastrointestinal events and hand-foot syndrome occur often with capecitabine, the tolerability profile is comparatively favorable. Prompt recognition of severe adverse effects is the key to successful management of capecitabine. Ongoing and future clinical trials will continue to examine, and likely expand, the role of capecitabine as a single agent and/or in combination with other anticancer agents for the treatment of gastrointestinal as well as other solid tumors, both in the advanced palliative and adjuvant settings. The author summarizes the current data on the role of capecitabine in the management of gastrointestinal cancers.

Keywords: 5-fluorouracil, capecitabine, chemotherapy, adjuvant, advanced, colon cancer, gastric cancer, hepatocellular cancer, pancreatic cancer, cholangiocarcinoma, rectal cancer, anal cancer

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at:

Other article by this author:

Current use and potential role of bevacizumab in the treatment of gastrointestinal cancers

Jia Li, Muhammad Wasif Saif

Biologics: Targets and Therapy 2009, 3:429-441

Published Date: 7 September 2009

Readers of this article also read:

An ensemble method approach to investigate kinase-specific phosphorylation sites

Datta S, Mukhopadhyay S

International Journal of Nanomedicine 2014, 9:2225-2239

Published Date: 10 May 2014

NanoDisk containing super aggregated amphotericin B: a high therapeutic index antifungal formulation with enhanced potency

Burgess BL, He Y, Baker MM, Luo B, Carroll SF, Forte TM, Oda MN

International Journal of Nanomedicine 2013, 8:4733-4743

Published Date: 12 December 2013

Update on the management of symptoms in schizophrenia: focus on amisulpride

Ann M Mortimer

Neuropsychiatric Disease and Treatment 2009, 5:267-277

Published Date: 18 May 2009

Nano rough micron patterned titanium for directing osteoblast morphology and adhesion

Sabrina Puckett, Rajesh Pareta, Thomas J Webster

International Journal of Nanomedicine 2008, 3:229-241

Published Date: 6 June 2008

Predator odor exposure facilitates acquisition of a leverpress avoidance response in rats

Francis X Brennan, Kevin D Beck, Richard J Servatius

Neuropsychiatric Disease and Treatment 2006, 2:65-69

Published Date: 15 March 2006